Tsai HY, et al. - Researchers performed this study to assess the determinants of receiving targeted therapy during the last month of life and to determine how targeted therapies affect the quality of end-of-life (EOL) care for patients with non-small-cell lung cancer. As per findings, they recommended considering targeted therapy at EOL a quality-of-care indicator. In the cessation of targeted therapy and the ongoing monitoring of practice initiatives, guidance seemed warranted. Further investigation seemed necessary for the decision-making processes associated with EOL care.